CPCatalyst Pharmaceuticals CPRX NASDAQ · Zdravstvo · Združene države Amerike
$31.49 -0.02% -$0.01
- Market cap
- $3.85B
- Enterprise value
- $3.10B
- P/E
- 17.4x
- Forward P/E
- -
- PEG
- 0.6x
- P/S
- 6.5x
- P/FCF
- 18.5x
- EV/EBITDA
- 11.1x
- ROIC
- 19.7%
- Bruto marža
- 122.0%
- Neto marža
- 37.1%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -2.7x
- Beta
- 0.74
- Free float
- 94.4%
O podjetju
Catalyst Pharmaceuticals, Inc. (CPRX) is an American biopharmaceutical company specializing in research, development, and commercialization of drugs for rare neurological disorders. With activities in biotechnology and pharmacology, Catalyst Pharmaceuticals is a key player in the world of innovative treatment approaches. Their research focuses on discovering new treatment options and therapies for patients with neurological disorders, such as Lambert-Eaton myasthenic syndrome (LEMS). The company aims to provide modern treatment solutions and improve the quality of life for patients with rare diseases. Catalyst Pharmaceuticals is characterized by expertise in pharmacology and neurology. Catalyst Pharmaceuticals, Inc. (CPRX) shares could be suitable for investors looking for an investment opportunity in the biopharmaceutical sector with a company that specializes in innovative treatment approaches and therapies for patients with rare neurological disorders.
Sektor
Zdravstvo
Panoga
Biotechnology
CEO
Richard John Daly
Zaposleni
182
Sedež
Coral Gables
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
- Kaj govori v prid: Dobiček na delnico je v zadnjih 3 letih rasel za 31 % letno.
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
- Kaj govori v prid: Od vsakih 100 USD prihodkov ostane 37 USD čistega dobička.
- Kaj govori v prid: Na vsakih 100 USD vloženega kapitala zasluži 20 USD letno.
Finančno zdravje
Ali zmore svoj dolg?
- Kaj govori v prid: Ima več denarja kot dolga: $517,6M proti $3,19M.
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke